Sun Pharmaceutical Industries Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 15,22,459 shares,. Its Average Traded Price (ATP) is ₹1754.83, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 2 @ ₹1758.80.
Sun Pharmaceutical Industries has an upper circuit limit of ₹1934.60 and a lower circuit limit of ₹1583.00. The total value traded stands at ₹267.17 CR, and the delivery percentage for the day is 65.93%.
The stock is currently traded with a market lot size of 1. Sun Pharmaceutical Industries also offers a dividend yield of 0.91%.
Sun Pharmaceutical Industries Share Price Chart
Sun Pharmaceutical Industries Share Key Metrics
Volume
15.22 L
Market Cap
421995.03 CR
LTQ@LTP
2@1758.80
ATP
1754.83
Var Margin
12.5 %
Circuit Range
1583-1934.6
Delivery %
65.93 %
Value
267.17 CR
ASM/GSM
No
Market Lot
1
Sun Pharmaceutical Industries Resistance and Support
Pivot 1758.7
Resistance
First Resistance
1783.3
Second Resistance
1802.6
Third Resistance
1827.2
Support
First Support
1739.4
Second Support
1714.8
Third Support
1695.5
Sun Pharmaceutical Industries Futures & Options
1758.8
-5.2 (-0.29%)
Sun Pharmaceutical Industries Option Chain
View Price, OI, Greeks & More...
27OCT26
1757.30
-7.20 (0.41%)
23NOV26
1766.70
-7.10 (0.40%)
29DEC26
1776.90
-10.00 (0.56%)
SUNPHARMA|27OCT26 CE 1740.00
29.60
-5.5 (-15.67%)
SUNPHARMA|27OCT26 PE 1760.00
21.15
2.35 (12.5%)
Sun Pharmaceutical Industries Shareholding Pattern
View More- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Sun Pharmaceutical Industries Corporate Actions
| Date | Agenda |
|---|---|
| 2026-10-30 | Quarterly Results |
| 2026-07-31 | Quarterly Results |
| 2026-05-22 | Audited Results & Final Dividend |
| 2026-01-31 | Quarterly Results & Interim Dividend |
| 2025-11-05 | Quarterly Results |
| 2025-07-31 | Quarterly Results |
| 2025-05-22 | Audited Results & Final Dividend |
| 2025-01-31 | Quarterly Results & Interim Dividend |
| 2024-10-28 | Quarterly Results |
| 2026-10-12 | Others |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-07 | 2026-07-07 | View More |
Sun Pharmaceutical Industries News
Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Intimation for Consideration And Approval The Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2026
Sun Pharmaceutical board is scheduled to meet on 30 October 2026 for financial results. The meeting will cover the quarter and half year ended 30 September 2026.
Oct 14 2026 20:16:45
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Credit Rating
CRISIL and ICRA have assigned AAA/Stable ratings to Sun Pharma's proposed Rs.15,000 crore Non-Convertible Debentures. Both agencies reaffirmed the existing ratings on commercial paper and bank facilities. The ratings factor in the company's profile and the proposed Organon acquisition.
Oct 13 2026 17:53:34
Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 12 October 2026
Sun Pharmaceutical's board approved the issuance of listed, unsecured, redeemable non-convertible debentures up to ₹10,000 crore on a private placement basis. Additionally, Gautam Doshi resigned as a Non-Executive, Independent Director effective October 12, 2026, due to personal reasons.
Oct 12 2026 19:56:53
Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Intimation for Consideration And Approval Of The Issuance Of Listed, Rated, Unsecured, Redeemable, Non-Convertible Debentures
Sun Pharmaceutical's board will meet on 12 October 2026 to consider issuing unsecured, redeemable non-convertible debentures up to Rs.15,000 crore. The issuance will be on a private placement basis in one or more tranches.
Oct 07 2026 20:39:10
Sun Pharmaceutical Industries Ltd - 524715 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Sun Pharma announces a postal ballot to approve ESOP 2026 and enabling financing limits, including ₹700 billion in borrowings, for the Organon acquisition. E-voting concludes on October 31, 2026.
Oct 01 2026 18:51:20
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma announced that LEQSELVI showed sustained efficacy and safety in treating severe alopecia areata over a two-year period. The data was presented at the EADV Congress 2026, with 93.9% of baseline responders maintaining their treatment response at Week 108.
Oct 01 2026 17:46:55
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharmaceutical and LIB Therapeutics announced a global licensing, commercialization, and manufacturing agreement for Lerodalcibep. This PCSK9 inhibitor is already approved in the EU and expands Sun Pharma's innovative medicines portfolio in the cardiovascular care market outside the US and China.
Sep 28 2026 08:20:01
Sun Pharmaceutical Industries Ltd - 524715 - Receipt Of Approval Of The Shareholders For Reclassification Of Shareholder Category
Sun Pharmaceutical shareholders approved the reclassification of individuals previously classified under the Promoter Group to the Public category. This reclassification, effective September 26, 2026, was done in accordance with SEBI Regulation 31A.
Sep 26 2026 22:17:51
Sun Pharmaceutical Industries Management
| Name | Position |
|---|---|
| Anoop Deshpande | Company Secretary & Compliance Officer |
| Dilip S Shanghvi | Chairman & Managing Director |
Sun Pharmaceutical Industries Similar Stocks
Divi's Laboratories Ltd.
9144.50
114.50 (1.27%)
Torrent Pharmaceuticals Ltd.
4558.90
-25.20 (0.55%)
Lenskart Solutions Ltd.
646.50
3.80 (0.59%)
Apollo Hospitals Enterprise Ltd.
7890.00
0.50 (0.01%)
Zydus Lifesciences Ltd.
1123.00
-17.20 (1.51%)
Laurus Labs Ltd.
2060.10
41.60 (2.06%)
Cipla Ltd.
1325.10
-2.90 (0.22%)
Dr. Reddy's Laboratories Ltd.
1233.00
14.20 (1.17%)
Mankind Pharma Ltd.
2275.50
-72.10 (3.07%)
Aurobindo Pharma Ltd.
1666.90
-11.00 (0.66%)
Sun Pharmaceutical Industries FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in SUNPHARMA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC